PT1163256E - Hemi-hidrato de 16-alfa-bromoepiandrosterona - Google Patents

Hemi-hidrato de 16-alfa-bromoepiandrosterona

Info

Publication number
PT1163256E
PT1163256E PT00918365T PT00918365T PT1163256E PT 1163256 E PT1163256 E PT 1163256E PT 00918365 T PT00918365 T PT 00918365T PT 00918365 T PT00918365 T PT 00918365T PT 1163256 E PT1163256 E PT 1163256E
Authority
PT
Portugal
Prior art keywords
hydrohate
bromepephandrosterone
hemi
alpha
bromepephandrosterone hemi
Prior art date
Application number
PT00918365T
Other languages
English (en)
Inventor
Patrick T Prendergast
Clarence Nathaniel Ahlem
James Martin Frincke
Luis Daniel De Carvalho Anjos
William Heggie
Christopher L Reading
Krupakar Paul Thadikonda
Russell Neil Vernon
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Publication of PT1163256E publication Critical patent/PT1163256E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
PT00918365T 1999-03-23 2000-03-23 Hemi-hidrato de 16-alfa-bromoepiandrosterona PT1163256E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12605699P 1999-03-23 1999-03-23
US14002899P 1999-06-16 1999-06-16
US41490599A 1999-10-08 1999-10-08
US16404899P 1999-11-08 1999-11-08

Publications (1)

Publication Number Publication Date
PT1163256E true PT1163256E (pt) 2004-07-30

Family

ID=27494614

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00918365T PT1163256E (pt) 1999-03-23 2000-03-23 Hemi-hidrato de 16-alfa-bromoepiandrosterona

Country Status (22)

Country Link
EP (1) EP1163256B1 (pt)
JP (1) JP2002540119A (pt)
KR (2) KR20070007394A (pt)
CN (1) CN1243767C (pt)
AP (1) AP2001002285A0 (pt)
AT (1) ATE259825T1 (pt)
AU (1) AU781997B2 (pt)
BR (1) BR0009476A (pt)
CA (1) CA2365081A1 (pt)
CZ (1) CZ20013420A3 (pt)
DE (1) DE60008353T2 (pt)
DK (1) DK1163256T3 (pt)
ES (1) ES2215631T3 (pt)
HK (1) HK1046002B (pt)
HU (1) HUP0203429A3 (pt)
IL (1) IL144916A0 (pt)
NO (2) NO320801B1 (pt)
NZ (1) NZ513803A (pt)
OA (1) OA11850A (pt)
PT (1) PT1163256E (pt)
RU (2) RU2295534C2 (pt)
WO (1) WO2000056757A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CA2386095A1 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US7241753B2 (en) 2000-02-25 2007-07-10 Loria Roger M Method of treatment of prostate cancer
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
FR2829697B1 (fr) * 2001-09-14 2004-03-19 Mayoly Spindler Lab Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
EP2298316A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
CN104072564B (zh) 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN106565654B (zh) * 2016-10-14 2018-08-31 云南中烟工业有限责任公司 一种从白云参中提取的新型黄酮类化合物、其制备方法及其用途
US10836788B2 (en) * 2019-02-05 2020-11-17 SD Chem, Inc. Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1314870C (en) * 1983-08-02 1993-03-23 Arthur G. Schwartz Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hypercholesterolemic agents
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
JPH0289327A (ja) * 1988-09-27 1990-03-29 Matsushita Electron Corp 銀ペースト塗布装置
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates

Also Published As

Publication number Publication date
KR100717897B1 (ko) 2007-05-14
DE60008353D1 (de) 2004-03-25
KR20020003217A (ko) 2002-01-10
JP2002540119A (ja) 2002-11-26
RU2417792C2 (ru) 2011-05-10
DK1163256T3 (da) 2004-06-28
HUP0203429A3 (en) 2004-07-28
ES2215631T3 (es) 2004-10-16
NZ513803A (en) 2004-06-25
AU781997B2 (en) 2005-06-23
IL144916A0 (en) 2002-06-30
EP1163256A1 (en) 2001-12-19
NO320801B1 (no) 2006-01-30
WO2000056757A1 (en) 2000-09-28
RU2006133273A (ru) 2008-03-27
AP2001002285A0 (en) 2001-12-31
HK1046002B (zh) 2006-10-20
HK1046002A1 (en) 2002-12-20
CA2365081A1 (en) 2000-09-28
CN1355809A (zh) 2002-06-26
CZ20013420A3 (cs) 2002-04-17
EP1163256B1 (en) 2004-02-18
DE60008353T2 (de) 2005-09-08
RU2001128881A (ru) 2003-09-27
BR0009476A (pt) 2002-02-19
NO20056167L (no) 2001-11-21
NO20014588D0 (no) 2001-09-21
KR20070007394A (ko) 2007-01-15
AU3919000A (en) 2000-10-09
OA11850A (en) 2006-03-06
NO20014588L (no) 2001-11-21
CN1243767C (zh) 2006-03-01
HUP0203429A2 (hu) 2003-01-28
ATE259825T1 (de) 2004-03-15
RU2295534C2 (ru) 2007-03-20

Similar Documents

Publication Publication Date Title
DE122007000064I2 (de) Erythropoietinkonjugate
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
DE60001283T2 (de) Celluloseetherfilme
PT1218009E (pt) Grandulos de quetiapina
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
PT1218096E (pt) Microcapsulas de libertacao variavel
DE50007953D1 (de) Beleuchtungsanordung
DE50008613D1 (de) Sicherungsring
PT1163256E (pt) Hemi-hidrato de 16-alfa-bromoepiandrosterona
NO20020773L (no) Borkronekobling
PT1235566E (pt) Formulacao injectavel de valnemulina
DE50000805D1 (de) Aufsitzspanner
DE50006899D1 (de) Antistatikum
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50003660D1 (de) Diacylhydrazinderivate
DE50003259D1 (de) Textilie
DE50006013D1 (de) Anschlagpuffer
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de) Piperidinalkohole
DE50009208D1 (de) Hydroxyphenylvinylthiazole
DE10082008D2 (de) Ausbeulgerät